Fiorenzo Santoleri1, Elena Ranucci2, Gaetano La Barba3, Irene Colasanto4, Matilde Scaldaferri4, Francesco Cattel4, Francesca Federici5, Chiara Rossi5, Katiuscia Di Biagio6, Anna Rita Scortechini7, Felice Musicco8, Giancarlo Torquati8, Angela Frazzetto8, Antonietta Vozza9, Caterina de Rosa9, Rosaria Lanzillo9, Maria Monteverde10, Luigia Luciano11, Fabrizio Pane11, Arianna Pasquazi12, Maria Grazia Celeste12, Maria Cantonetti13, Luca Franceschini13, Manuela Rizzo13, Alberto Costantini1. 1. Hospital pharmacist, Pescara General Hospital, Pescara, Italy. 2. Department Pharmacist, Hematological Oncology Department, Pescara General Hospital, Pescara, Italy. 3. Hematologist, Hematological Oncology Department, Pescara General Hospital, Pescara, Italy. 4. Hospital pharmacist, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy. 5. Hospital pharmacist, ASUR Marche, Ancona, Italy. 6. Environmental Epidemiology Unit - Regional Environmental Protection Agency of Marche, Ancona, Italy. 7. Hematologist, Hematology Unit, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy. 8. Hospital Pharmacist at Regina Elena - San Gallicano cancer and dermatological Institute, Rome, Italy. 9. Hospital pharmacist, Azienda Ospedaliera Universitaria "Federico II", Napoli, Italy. 10. Biologist, Department of Clinical Medicine and Surgery, Federico II University Medical School, Napoli, Italy. 11. Hematologist, Department of Clinical Medicine and Surgery, Federico II University Medical School, Napoli, Italy. 12. Hospital pharmacist, Policlinico Tor Vergata PTV Foundation, Roma, Italy. 13. Hematologist, Unit of Lymphoproliferative Disorders, Policlinico Tor Vergata PTV Foundation, Roma, Italy.
Abstract
BACKGROUND: The use of dasatinib and nilotinib in the treatment of patients with chronic myeloid leukemia represents a valid therapeutic option for patients resistant or intolerant to imatinib. In this multicentre study, adherence, persistence and efficacy in real life over two years of treatment were evaluated. MATERIALS AND METHODS: Adherence to treatment was calculated as the ratio between the dose received and the prescribed dose. The dose received was calculated using pharmacy refill data. The persistence with treatment was calculated as the difference between the end and the beginning of the treatment. Efficacy was assigned as Progression-Free Survival (PFS) and Events-Free Survival (EFS) and represented through the Kaplan-Meier curve. RESULTS: The number of patients analysed was 117, 70 treated with dasatinib and 47 with nilotinib. Adherence to treatment for dasatinib and nilotinib at two years was 0.91 and 0.82 respectively. Persistence at two years was 77% while the PFS was 92% for both drugs in the study. CONCLUSION: Adherence to the treatment calculated over two years showed a superiority of dasatinib over nilotinib. Nevertheless, the efficacy in terms of PFS and EFS is superimposable between the two drugs in the study.
BACKGROUND: The use of dasatinib and nilotinib in the treatment of patients with chronic myeloid leukemia represents a valid therapeutic option for patients resistant or intolerant to imatinib. In this multicentre study, adherence, persistence and efficacy in real life over two years of treatment were evaluated. MATERIALS AND METHODS: Adherence to treatment was calculated as the ratio between the dose received and the prescribed dose. The dose received was calculated using pharmacy refill data. The persistence with treatment was calculated as the difference between the end and the beginning of the treatment. Efficacy was assigned as Progression-Free Survival (PFS) and Events-Free Survival (EFS) and represented through the Kaplan-Meier curve. RESULTS: The number of patients analysed was 117, 70 treated with dasatinib and 47 with nilotinib. Adherence to treatment for dasatinib and nilotinib at two years was 0.91 and 0.82 respectively. Persistence at two years was 77% while the PFS was 92% for both drugs in the study. CONCLUSION: Adherence to the treatment calculated over two years showed a superiority of dasatinib over nilotinib. Nevertheless, the efficacy in terms of PFS and EFS is superimposable between the two drugs in the study.
Entities:
Keywords:
Dasatinib; chronic myeloid leukaemia; drug used study; effectiveness; medication adherence; nilotinib; persistence